{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:12:25Z","timestamp":1786119145649,"version":"build-2736575974"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1097\/spc.0b013e32830baac2","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T16:54:54Z","timestamp":1236272094000},"page":"197-203","source":"Crossref","is-referenced-by-count":40,"title":["RANKL inhibition in the treatment of bone metastases"],"prefix":"10.1097","volume":"2","author":[{"given":"Allan","family":"Lipton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210126","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"R2-9-20210126","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"Br J Cancer"},{"key":"R3-9-20210126","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"R4-9-20210126","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q","article-title":"The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma","volume":"88","author":"Carlin","year":"2000","journal-title":"Cancer"},{"key":"R5-9-20210126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8040","article-title":"A systematic review of the role of bisphosphonates in metastatic disease","volume":"8","author":"Ross","year":"2004","journal-title":"Health Technol Assess"},{"key":"R6-9-20210126","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1517\/14656566.9.6.937","article-title":"Pharmacotherapy of bone metastases in breast cancer patients","volume":"9","author":"Petrut","year":"2008","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 1","key":"R7-9-20210126","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1634\/theoncologist.10-90001-19","article-title":"Bisphosphonate treatment recommendations for oncologists","volume":"10","author":"von Moos","year":"2005","journal-title":"Oncologist"},{"key":"R8-9-20210126","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1210\/endo.137.9.8756585","article-title":"The human osteoclast precursor circulates in the monocyte fraction","volume":"137","author":"Fujikawa","year":"1996","journal-title":"Endocrinology"},{"key":"R9-9-20210126","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S8756-3282(02)00672-5","article-title":"Osteoclastic acidification pathways during bone resorption","volume":"30","author":"Rousselle","year":"2002","journal-title":"Bone"},{"key":"R10-9-20210126","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/(SICI)1097-4644(1998)72:30\/31+<73::AID-JCB11>3.0.CO;2-L","article-title":"Bone stem cells","volume":"30\u201331","author":"Aubin","year":"1998","journal-title":"J Cell Biochem Suppl"},{"key":"R11-9-20210126","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ctrv.2007.09.002","article-title":"RANK ligand as a therapeutic target for bone metastases and multiple myeloma","volume":"34","author":"Roodman","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"R12-9-20210126","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1586\/14737140.7.2.221","article-title":"Key roles of the OPG-RANK-RANKL system in bone oncology","volume":"7","author":"Baud'huin","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"R13-9-20210126","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/8756-3282(94)90703-X","article-title":"Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer","volume":"15","author":"Taube","year":"1994","journal-title":"Bone"},{"key":"R15-9-20210126","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2141.1995.tb05609.x","article-title":"Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo","volume":"90","author":"Bataille","year":"1995","journal-title":"Br J Haematol"},{"key":"R17-9-20210126","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/clinchem\/45.8.1240","article-title":"Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases","volume":"45","author":"Berruti","year":"1999","journal-title":"Clin Chem"},{"key":"R18-9-20210126","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1002\/1097-0142(20000615)88:12+<3047::AID-CNCR22>3.0.CO;2-U","article-title":"Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton","volume":"88","author":"Papapoulos","year":"2000","journal-title":"Cancer"},{"key":"R19-9-20210126","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1464-410X.1991.tb15260.x","article-title":"Morphometric evidence for bone resorption and replacement in prostate cancer","volume":"68","author":"Clarke","year":"1991","journal-title":"Br J Urol"},{"key":"R20-9-20210126","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1022627421000","article-title":"Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results","volume":"20","author":"Roudier","year":"2003","journal-title":"Clin Exp Metastasis"},{"key":"R21-9-20210126","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2967\/jnumed.107.045666","article-title":"Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET\/CT","volume":"49","author":"Hsu","year":"2008","journal-title":"J Nucl Med"},{"key":"R22-9-20210126","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R23-9-20210126","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1210\/endo.139.3.5837","article-title":"Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG\/OCIF inhibits osteoclastogenesis in vitro","volume":"139","author":"Yasuda","year":"1998","journal-title":"Endocrinology"},{"key":"R24-9-20210126","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"R25-9-20210126","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"R26-9-20210126","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0002-9440(10)64942-5","article-title":"Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation","volume":"156","author":"Huang","year":"2000","journal-title":"Am J Pathol"},{"key":"R27-9-20210126","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/pros.20678","article-title":"RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes","volume":"68","author":"Armstrong","year":"2008","journal-title":"Prostate"},{"key":"R29-9-20210126","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.0105-2896.2005.00327.x","article-title":"Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system","volume":"208","author":"Tanaka","year":"2005","journal-title":"Immunol Rev"},{"key":"R30-9-20210126","doi-asserted-by":"crossref","first-page":"28355","DOI":"10.1074\/jbc.273.43.28355","article-title":"The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor","volume":"273","author":"Wong","year":"1998","journal-title":"J Biol Chem"},{"key":"R31-9-20210126","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1534-5807(02)00369-6","article-title":"Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts","volume":"3","author":"Takayanagi","year":"2002","journal-title":"Dev Cell"},{"key":"R32-9-20210126","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s007740300021","article-title":"Signal transduction pathways regulating osteoclast differentiation and function","volume":"21","author":"Tanaka","year":"2003","journal-title":"J Bone Miner Metab"},{"key":"R33-9-20210126","doi-asserted-by":"crossref","first-page":"36846","DOI":"10.1074\/jbc.M606656200","article-title":"Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand","volume":"281","author":"Hikita","year":"2006","journal-title":"J Biol Chem"},{"key":"R34-9-20210126","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1210\/endo.141.9.7634","article-title":"Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function","volume":"141","author":"Udagawa","year":"2000","journal-title":"Endocrinology"},{"key":"R35-9-20210126","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev"},{"key":"R36-9-20210126","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"R37-9-20210126","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1073\/pnas.97.4.1566","article-title":"RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism","volume":"97","author":"Li","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R38-9-20210126","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1084\/jem.192.4.463","article-title":"Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis","volume":"192","author":"Min","year":"2000","journal-title":"J Exp Med"},{"key":"R39-9-20210126","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1006\/bbrc.1998.8697","article-title":"Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor\/osteoprotegerin","volume":"247","author":"Mizuno","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"R40-9-20210126","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"R41-9-20210126","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S8756-3282(99)00162-3","article-title":"Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells","volume":"25","author":"Hofbauer","year":"1999","journal-title":"Bone"},{"key":"R42-9-20210126","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.4049\/jimmunol.169.6.3353","article-title":"IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae","volume":"169","author":"Palmqvist","year":"2002","journal-title":"J Immunol"},{"key":"R43-9-20210126","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1002\/1097-0142(20000615)88:12+<2892::AID-CNCR2>3.0.CO;2-Y","article-title":"Molecular mechanisms of osteolytic bone metastases","volume":"88","author":"Guise","year":"2000","journal-title":"Cancer"},{"key":"R44-9-20210126","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1210\/endo.139.11.6433","article-title":"Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells","volume":"139","author":"Horwood","year":"1998","journal-title":"Endocrinology"},{"key":"R45-9-20210126","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1210\/endo.140.8.6887","article-title":"Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation","volume":"140","author":"Lee","year":"1999","journal-title":"Endocrinology"},{"key":"R46-9-20210126","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1210\/endo.140.10.7037","article-title":"Breast cancer cells interact with osteoblasts to support osteoclast formation","volume":"140","author":"Thomas","year":"1999","journal-title":"Endocrinology"},{"key":"R47-9-20210126","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1006\/bbrc.1998.8783","article-title":"Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells","volume":"247","author":"Brandstrom","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"R48-9-20210126","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1359\/jbmr.1999.14.9.1478","article-title":"A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3","volume":"14","author":"Morony","year":"1999","journal-title":"J Bone Miner Res"},{"key":"R49-9-20210126","first-page":"4432","article-title":"Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis","volume":"61","author":"Morony","year":"2001","journal-title":"Cancer Res"},{"key":"R50-9-20210126","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1172\/JCI11685","article-title":"Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone","volume":"107","author":"Zhang","year":"2001","journal-title":"J Clin Invest"},{"key":"R51-9-20210126","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10585-007-9127-1","article-title":"Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis","volume":"25","author":"Canon","year":"2008","journal-title":"Clin Exp Metastasis"},{"key":"R52-9-20210126","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 1","key":"R53-9-20210126","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0305-7372(06)80003-4","article-title":"Bone markers and current laboratory assays","volume":"32","author":"Hannon","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"R54-9-20210126","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R55-9-20210126","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/sj.bjc.6601437","article-title":"Bone resorption predicts for skeletal complications in metastatic bone disease","volume":"89","author":"Brown","year":"2003","journal-title":"Br J Cancer"},{"key":"R56-9-20210126","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2002.20.3.850","article-title":"Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status","volume":"20","author":"Costa","year":"2002","journal-title":"J Clin Oncol"},{"key":"R57-9-20210126","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"R58-9-20210126","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1210\/jc.2005-0183","article-title":"Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R59-9-20210126","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/JTO.0b013e3181651c0e","article-title":"Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity","volume":"3","author":"Hirsh","year":"2008","journal-title":"J Thorac Oncol"},{"key":"R60-9-20210126","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0959-8049(98)00277-9","article-title":"Markers of bone resorption in patients treated with pamidronate","volume":"34","author":"Lipton","year":"1998","journal-title":"Eur J Cancer"},{"key":"R61-9-20210126","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0093-7754(01)90233-7","article-title":"Use of markers of bone turnover for monitoring bone metastases and the response to therapy","volume":"28","author":"Lipton","year":"2001","journal-title":"Semin Oncol"},{"key":"R62-9-20210126","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1158\/1078-0432.CCR-03-0735","article-title":"Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer","volume":"10","author":"Michaelson","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R63-9-20210126","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma","volume":"20","author":"Menssen","year":"2002","journal-title":"J Clin Oncol"},{"key":"R64-9-20210126","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol"},{"key":"R65-9-20210126","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/172460080201700405","article-title":"Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases","volume":"17","author":"Berruti","year":"2002","journal-title":"Int J Biol Markers"},{"key":"R66-9-20210126","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/annonc\/mdh089","article-title":"Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis","volume":"15","author":"Ali","year":"2004","journal-title":"Ann Oncol"},{"key":"R67-9-20210126","first-page":"1457","article-title":"Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid","volume":"25","author":"Pectasides","year":"2005","journal-title":"Anticancer Res"},{"key":"R68-9-20210126","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"key":"R69-9-20210126","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/10428194310001593193","article-title":"The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression","volume":"45","author":"Roux","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"R70-9-20210126","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R71-9-20210126","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1200\/jco.2006.24.18_suppl.8562","article-title":"A randomized trial of denosumab (AMG 162) versus intravenous bisphosphonates in cancer patients with bone metastases on established IV BP and evidence of elevated bone resorption [abstract]","volume":"24","author":"Suarez","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"R72-9-20210126","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/ar2171","article-title":"Clinical development of anti-RANKL therapy","volume":"9","author":"Schwarz","year":"2007","journal-title":"Arthritis Res Ther"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/SPC.0b013e32830baac2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:40:38Z","timestamp":1786038038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01263393-200809000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0b013e32830baac2","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}